ClickHouse Acquires HyperDX to Accelerate the Future of Observability
ClickHouse, the company behind the world's fastest analytical database, today announced the acquisition of HyperDX, an open-source observability platform built on ClickHouse. This strategic acquisition reinforces ClickHouse's commitment to delivering the fastest, most cost-effective, and scalable solutions to developers and enterprises worldwide; including observability.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250313954782/en/
ClickHouse, the company behind the world's fastest analytical database, today announced the acquisition of HyperDX, an open-source observability platform built on ClickHouse. (Graphic: Business Wire)
The acquisition combines ClickHouse's unmatched performance and scalability with HyperDX's developer-first experience, creating a comprehensive observability platform that seamlessly integrates session replay, exceptions, logs, infrastructure metrics, and distributed tracing through an OpenTelemetry-native approach.
“ClickHouse’s analytics capabilities and open ecosystem make it a powerful technology for observability. However, the end-user experience lacked some of the comprehensive features of more established solutions. HyperDX is very exciting, bringing together an enhanced query experience with a more intuitive UI for exploratory observability workflows.”
Viktor Eriksson, Lovable
"Observability is fundamentally a data problem," said Tanya Bragin, VP of Product & Marketing at ClickHouse. "The dataset size dictates how difficult and expensive it will be to build an observability platform. That's why ClickHouse has been the backbone of observability platforms for years, powering logging, metrics, and tracing solutions at companies like eBay and Netflix."
ClickHouse originally explored new observability solutions while transitioning from Datadog to their in-house LogHouse stack (How we Built a 19 PiB Logging Platform with ClickHouse and Saved Millions), which was built on ClickHouse to handle their petabyte-scale workloads. During this process, they discovered HyperDX and saw how easily it could transform an existing ClickHouse deployment into a full observability platform.
"When we started HyperDX, we had two core beliefs: we wanted to build the best open-source observability platform, and ClickHouse was the ONLY database to power it," said Michael Shi, CEO at HyperDX. "Our mission has always been to help engineers diagnose and resolve production issues faster, and ClickHouse has been a foundational part of that journey from day one."
The Future of Open-Source Observability
Through conversations, the companies discovered they shared the same vision:
- Observability should be cost-effective and developer-friendly
- ClickHouse's performance and scalability make it the best foundation for observability
- HyperDX's developer-first experience makes it effortless for teams to implement
The integration provides numerous benefits, including:
- Standards-Based Data Collection – Both ClickHouse and HyperDX are committed to OpenTelemetry, with ClickHouse now maintaining the ClickHouse OpenTelemetry exporter
- Open-Source First – Making robust observability accessible to everyone, with cloud offerings providing a simple, cost-effective operational experience
- Flexible Data Access – Direct access to observability data with multiple analysis options
- Blazing Fast Performance – Query terabytes in seconds for real-time troubleshooting
HyperDX Cloud will continue serving and onboarding new customers, and the open-source project will remain actively maintained and developed. At the same time, the joint roadmap focuses on bringing even more powerful observability tools to engineers.
Getting Started
Explore more details on the ClickHouse Blog (ClickHouse acquires HyperDX: the future of open-source observability) or the HyperDX blog (ClickHouse acquires HyperDX to accelerate the future of open-source observability).
If you want to try HyperDX, you can get started for free on our cloud or self-host it on your own infrastructure.
About ClickHouse
ClickHouse is the company behind the world's fastest open-source analytical database management system. Used by companies including eBay, Netflix, and Cloudflare, ClickHouse enables the processing of petabyte-scale datasets with unmatched efficiency and cost-effectiveness.
About HyperDX
HyperDX is an open-source observability platform built on ClickHouse that provides a seamless OpenTelemetry-native experience. It integrates session replay, exceptions, logs, infrastructure metrics, and distributed tracing to help engineers diagnose and resolve production issues faster.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250313954782/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ImmunAbs Announces FDA Phase 2 IND Approval of IM-101, a Novel Complement C5 Inhibitor, for Treatment of Myasthenia Gravis2.6.2025 13:00:00 CEST | Press release
ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial evaluating the safety and efficacy of IM-101, a novel complement C5 inhibitor, for the treatment of Myasthenia Gravis. The forthcoming multicenter, randomized, double-blind, placebo-controlled study will enroll up to 90 patients to evaluate the effectiveness and safety of monthly IM-101 dosing in relieving complement-induced symptoms in MG. “This IND approval is pivotal for us as it brings us one step closer to delivering a transformative therapy for patients with autoimmune disorders”, said Dr. Dongjo Kim, the CEO of ImmunAbs, “we believe IM-101 has the potential to deliver deeper therapeutic responses and more durable remissions in patients who have failed to achieve sustained remission with current approved treatment.” About Myasthenia Gravis
Lenovo and Bellevue University Team Up to Offer Supply Chain and Logistics Education to Deliver “Smarter Technology for All”2.6.2025 13:00:00 CEST | Press release
Learners will have access to Lenovo’s globally recognized supply chain expertise through real-world case studies and subject matter experts. Lenovo, the global technology powerhouse, recognized in the top 10 in the Gartner Supply Chain Top 25, and Bellevue University, one of the nation’s top online universities, are teaming up to develop the next generation of supply chain professionals. “We believe that bringing real-world Global Supply Chain experience and learning directly into an education curriculum is precisely the optimal way to upskill the workforce of the future,” said Ben Massie, Vice President, Global Supply Chain, Lenovo. “Teaming up with Bellevue allows us to attract the right talent using the right technology and deliver on our mission to make ‘smarter technology for all’ a reality.” As a preferred higher education institution tapped to team up with Lenovo to offer supply chain short-term learning, Bellevue will leverage the breadth and depth of Lenovo’s supply chain expe
Lifezone Metals Files Initial Assessment for the Kabanga Nickel Project in Tanzania2.6.2025 12:30:00 CEST | Press release
Vertically Integrated Plan includes Hydrometallurgical Refinery at Kahama $2.37 Billion After-Tax NPV (8%) and 22.9% After-Tax IRR at $8.49 per Pound Nickel Price Initial Assessment Proposes a 22-Year Mine Plan at Average 2.39% Nickel Equivalent Grade Webcast with Technical Leadership Team at 10 AM ET on Tuesday, June 3, 2025 Lifezone Metals Limited’s (NYSE: LZM) Chief Executive Officer, Chris Showalter, and Chief Operating Officer, Gerick Mouton, announce today the results from the Initial Assessment for its flagship Kabanga Nickel Project in northwest Tanzania. The Initial Assessment evaluates a vertically integrated mining, processing and refining operation, commencing with a high-grade nickel sulfide underground mine and concentrator at the Kabanga site, followed five years later by a hydrometallurgical refinery at Kahama. The study covers the Main, MNB, Kima, North, and Tembo zones and is based on the December 2024 Mineral Resource Update (refer to Lifezone’s December 5, 2024 news
Corpay Cross-Border Named an Official Partner of Real Madrid C.F.2.6.2025 12:00:00 CEST | Press release
Providing access to currency risk management and cross-border payments solutions Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into an agreement with Real Madrid C.F. to become an Official Partner. Through this partnership, Real Madrid will be able to gain access to and utilise Corpay Cross Border’s innovative solutions to help mitigate foreign exchange exposure from their day-to-day business needs. "The Corpay Cross-Border team is elated to be named an Official Partner of Real Madrid, one of the world’s most widely recognized and followed sports franchises," said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions. “With our strong focus on growing the Corpay brand, as well as our currency risk management business, we are excited to partner with one of the most successful football clubs in the world.” About Corpay Corpay, Inc. (NYSE: CPAY) is a global S&P500 corporate payments co
BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 20252.6.2025 12:00:00 CEST | Press release
Preliminary results highlight anti-tumor activity and favorable safety profiles of both B7-H4-targeting ADC and CDK2 inhibitorData underscore strength of emerging breast cancer pipeline as part of BeOne’s global transformation with next wave of innovation BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, announced new clinical data from its emerging breast cancer pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Poster presentations feature preliminary results of the dose escalation studies of two investigational molecules: BG-C9074, a novel B7-H4-targeting antibody-drug conjugate (ADC) in patients with advanced solid tumors, including breast cancer, and BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), in HR+/HER2- breast cancer patients with prior CDK4/6i exposure. “Presenting the first clinical data for two novel breast cancer candidates at ASCO 2025 marks a pivotal moment for BeOne,” said Mark Lanas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom